Representative before the EPO

Employment test 51 - 200 employees
Company dna mathys and squire llp
no operation time available
Headquarter in London and 5 offices
active in Legal Services and Matchmaking and Trading

Representative before the EPO

Employment test 51 - 200 employees
Company dna j a kemp
no operation time available
1350.83
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Representative before the EPO

Company dna finnegan europe llp
operating since 2013
Headquarter in London and 1 office
active in Legal Services

We have observed 25 EP applications Hazel Ford has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after November 16, 2014). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13811325

COMPOUNDS, COMPOSITIONS AND METHODS USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS

IPC classification:
A61K 31/7034, A61P 35/00
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
The patent has been granted
EP14762642

POLYSIALIC ACID, BLOOD GROUP ANTIGENS AND GLYCOPROTEIN EXPRESSION

IPC classification:
C12P 19/28, C12P 19/08, C12N 15/00
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
EXAMINATION REQUESTED
EP15816329

BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA

IPC classification:
C12R 1/01, C12P 13/10, C12N 15/70, C12N 15/52, C12R 1/19, C12N 9/10
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Agent:
Malcolm Charles Main, Murgitroyd & Company
Status:
Request for examination was made
EP15864529

SUBSTITUTED PYRIDINES AS BROMODOMAIN INHIBITORS

IPC classification:
C07D 417/14, C07D 413/14, A61K 31/4439, C07D 413/04
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
The patent has been granted
EP15865762

HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

IPC classification:
A61K 31/7034, C07H 15/207
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
The patent has been granted
EP15865252

SUBSTITUTED PYRIDINONES AS BROMODOMAIN INHIBITORS

IPC classification:
C07D 417/14, C07D 413/14, A61K 31/4439, C07D 413/04
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP15866917

SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS

IPC classification:
C07D 413/14, C07D 403/04, C07D 401/14, A61K 31/4985, A61K 31/4439, A61K 31/4196, C07D 403/14
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP15869419

INHIBITORS OF BROMODOMAINS

IPC classification:
C07D 471/04, A61K 31/4439, A61K 31/437, A61K 31/42, C07D 413/14
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16710574

BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER

IPC classification:
C12N 15/74, C12N 15/70, A61K 35/74
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Agent:
Murgitroyd & Company
Status:
Request for examination was made
EP16764296

COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES

IPC classification:
C07D 239/91, A61P 37/02, A61K 31/517, A61K 31/551
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16724834

BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER

IPC classification:
A61K 35/74, C07K 14/195
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Agent:
Murgitroyd & Company
Status:
Request for examination was made
EP16728448

BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA

IPC classification:
C12N 5/10, C12N 9/88, A61K 35/74, C07K 14/195
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Agent:
Murgitroyd & Company
Status:
Request for examination was made
EP16733783

BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID

IPC classification:
A61K 35/74, C12N 1/00
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Agent:
Murgitroyd & Company
Status:
Request for examination was made
EP16734042

FACTOR XI ANTIBODIES AND METHODS OF USE

IPC classification:
C07K 16/36
Applicant:
Novartis AG
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Tamaris Clare Bucher, Novartis Pharma AG
Status:
Request for examination was made
EP16833728

METHODS FOR THE MOBILIZATION AND USE OF T-CELLS WITH ENHANCED RECONSTITUTION POTENTIAL AND LIFE-SPAN

IPC classification:
C12N 5/0783, A61K 35/17
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16751733

BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING PROPIONATE CATABOLISM

IPC classification:
A61K 35/74, C12N 1/00
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Murgitroyd & Company
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16766160

BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL

IPC classification:
C12N 1/00, A61K 35/74
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Murgitroyd & Company
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16771037

BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER

IPC classification:
A23L 33/135, C12N 1/20, A61K 35/741, A61K 35/74, A61K 31/404, C12R 1/01, C12N 15/70, C12R 1/19
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP16810138

BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA

IPC classification:
C12N 5/10, C12N 9/88, A61K 35/74, C07K 14/195
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Hazel Ford, Finnegan Europe LLP
Status:
Request for examination was made
EP17702489

GLYCOMIMETIC INHIBITORS OF PA-IL AND PA-IIL LECTINS

IPC classification:
A61K 31/7034, A61P 31/04, G01N 33/569, C07H 15/207
Agent:
Hazel Ford, Mathys & Squire LLP
Status:
Request for examination was made
EP18193312

NOVEL ANTI-INFLAMMATORY AGENTS

IPC classification:
C07D 239/91, A61K 31/47
Agent:
Hazel Ford, Mathys & Squire LLP
Status:
Request for examination was made
EP17730936

REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/00, C07K 16/42
Applicant:
Novartis AG
Agent:
Hazel Ford, Mathys & Squire LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
Request for examination was made
EP17791785

HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS

IPC classification:
A61P 35/00, C07H 15/26, C07H 15/207, A61K 47/60
Agent:
Hazel Ford, Mathys & Squire LLP
Status:
Request for examination was made
EP17835501

FACTOR XI ANTIBODIES AND METHODS OF USE

IPC classification:
A61P 7/02, A61K 39/395, C07K 16/40, C07K 16/36
Applicant:
Novartis AG
Agent:
Hazel Ford, Mathys & Squire LLP
Status:
Request for examination was made
EP18701238

MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS

IPC classification:
C12N 15/74, C12N 15/70, A61K 35/74
Agent:
Hazel Ford, Mathys & Squire LLP
Status:
Request for examination was made

Please Sign in to use this feature